Temps are falling and so is investor cash as BioSpace reviewed which biotech companies are scooping up the dollars.

The U.S. Food and Drug Administration approved Immunocore’s Kimmtrak (tebentafusp-tebn) for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma (mUM). 

Cellino Biotech announced a completed Series A financing of $80 million led by the impact investment arm of Bayer AG, Leaps by Bayer, 8VC, and Humboldt Fund and includes new investor Felicis Ventures.

Affini-T Therapeutics, a new cell therapy company launched by researchers from Fred Hutchinson Cancer Center, made its public debut at the 2022 J.P. Morgan Healthcare Conference with a mission to target oncogenic driver mutations to deliver transformative therapies intended to cure patients.

Amgen Chief Executive Officer Robert Bradway is excited about 2022. During his presentation at the J.P. Morgan Healthcare Conference, Bradway said things are lining up for long-term growth for the California-based company. 

Brisbane, California-based Sangamo Therapeutics announced that Sanofi US was returning rights to SAR445136 as the Paris-based company shifts its approach from personalized cell therapies to allogeneic off-the-shelf genomic approaches.

CGT supply chain mastery starts with a clear understanding of the patient journey and product journey and how these two journeys diverge from processes companies have established to support other modalities.

EVERSANA, a pioneer of next-generation commercial services to the global life sciences industry, announced its membership in the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), the region’s principal trade association for small to medium-sized companies in the pharmaceutical, biotech and medtech industries.

Japan’s Takeda Pharmaceutical announced deals with two biotech companies, Seattle-based Immusoft and San Diego’s Poseida Therapeutics.

Massachusetts-based Kytopen has seen an influx of cash during the past few months. Most recently, the biotech raised a large chunk of money in the company’s Series A funding round, which was announced on Sept. 28.